Maze Therapeutics Appoints Sekar Kathiresan, MD, to its Board of Directors

Maze Therapeutics Appoints Sekar Kathiresan, MD, to its Board of Directors

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Maze Therapeutics, a company that translates genetic knowledge into new precision medicines, today announced that Sekar Kathiresan, MD, co-founder of Maze, has joined the company’s board of directors. Dr. Kathiresan is an experienced cardiologist, co-founder and CEO of Verve Therapeutics, and a lecturer in medicine at Harvard Medical School. His work has focused on harnessing human genetics to understand the root causes of disease and improve preventive care. Among his scientific contributions, Dr. Kathiresan has helped uncover novel biological mechanisms underlying heart attacks, discovered mutations that protect against heart attack risk, and developed a genetic test for personalized heart attack prevention.

“Sek has dedicated his career to creating a better understanding of the genetic factors of cardiovascular disease in order to provide better patient care, just as we at Maze have dedicated our research to better understanding the genetic factors of disease and transforming this knowledge into meaningful medicines,” said Jason Coloma, Ph.D., President and CEO of Maze. “His vast experiences as a practicing cardiologist, scientist and now Chief Biotechnology Officer bring important perspective to Maze as we apply learnings from our Compass platform to discover and advance programs for patients in need. We are delighted to welcome him to the Board of Directors and I look forward to partnering with him. .

“Maze seeks to leverage insights from genetics to develop impactful new treatments and transform the future of medicine,” said Dr. Kathiresan. “As co-founder of Maze, I am thrilled to have witnessed the progress the company has made with its platform and programs in just a few years. Maze has grown from a concept in 2019 to a company that has already launched a clinical program and continues to develop a robust platform and pipeline.I am proud to join the Board of Directors and contribute to the continued growth of Maze.

Prior to Verve, Dr. Kathiresan has served as Director of the Center for Genomic Medicine at Massachusetts General Hospital (MGH), Director of the Cardiovascular Disease Initiative at the Broad Institute, and Professor of Medicine at Harvard Medical School, among others. There, Dr. Kathiresan’s research lab focused on understanding the hereditary basis of blood lipids and myocardial infarction. For his contributions to research, he has been recognized by the American Heart Association with its highest scientific honor, a Distinguished Scientist Award, and by the American Society of Human Genetics with the 2018 Curt Stern Award. Dr. Kathiresan is a graduate summa cum laude with a BA in history from the University of Pennsylvania and earned his MD from Harvard Medical School. He completed his clinical training in internal medicine and cardiology at the MGH and his postdoctoral research training in human genetics at the Framingham Heart Study and the Broad Institute.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company that applies advanced data science methods in tandem with a robust suite of research and development capabilities to advance a pipeline of novel precision medicines for patients with genetically defined diseases. Maze has developed the Maze Compass™ platform, a proprietary, purpose-built platform that combines human genetic data, functional genomics tools, and data science technology to map novel connections between known genes and their influence on susceptibility, time of onset and rate of disease progression. Using Compass, Maze is building a broad portfolio of wholly owned and partnered programs. Maze is based in South San Francisco. For more information, visit mazetx.com or follow us on LinkedIn and Twitter.


#Maze #Therapeutics #Appoints #Sekar #Kathiresan #Board #Directors

Leave a Comment

Your email address will not be published.